An experimental COVID-19 vaccine developed by pharmaceutical company Pfizer in tandem with biotech company BioNTech shows promising impact on limiting the spread of the disease in early clinical trials.
As reported by CNBC, the unnamed drug spurred an immune response in test subjects receiving larger doses of the drug, producing antibodies against the SARS-CoV-2 virus, which causes COVID-19. Some of the antibodies produced induced a neutralizing effect on the virus, necessary to creating a immunity.
The drug spurred side effects, such as high fever, in the small test group of 45 patients, which also included a control group who received a placebo.